RLMDNCMHealthcare·Biotechnology#182 in industry

Relmada Therapeutics, Inc.

Reports in 14d· 2026-05-11

+71.5% · 90d

$7.03

-0.18 (-2.50%)

After-Hours $7.03(+0.00)

News

(1)

April 2026

Apr 6, 20263 weeks agoPRE 14AHealthcare

RELMADA THERAPEUTICS, INC. — PRE 14A Filing

RLMDRELMADA THERAPEUTICS, INC.

# 🧾 What This Document Is This is a **preliminary proxy statement** (PRE 14A) for Relmada Therapeutics. Its main purpose is to tell shareholders about the company's annual meeting and give them the information they need to vote on important proposals. 👉 **Why it matters:** As a shareholder, this

Read summaryView on SEC EDGAR

Key Data

Market Cap$737.4M

Open$7.21

Prev Close$7.21

Day Range$6.89 – $7.58

52W Range$0.27 – $7.94

Volume1,402,812

P/E (TTM)—

EPS$-1.45

Dividend Yield—

Beta—

Price Target$12.80(+82.1%)

Next Earnings2026-05-11(14d)

Analyst Ratings

Strong Buy5 analysts

Buy 5Hold 0Sell 0

About

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Healthcare · Biotechnology

17 employees

www.relmada.com